Fintel reports that on December 18, 2025, Brookline Capital upgraded their outlook for Verrica Pharmaceuticals (NasdaqCM:VRCA) from Hold to Buy. Analyst Price Forecast Suggests 106.19% Upside As of ...
16:20 EST Verrica Pharmaceuticals (VRCA) files to sell 14.76M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. The consensus rating for Verrica Pharmaceuticals is ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback